Natco Pharma share price today

Natco Pharma Ltd's share price was ₹788.75 at the close on 4 November 2026. It has been falling for 14 weeks. That is 11.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹783 and ₹1,199, and at that close it sat 2% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Natco Pharma Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 12 weeks running.

Over the last 11 years the share price moved +87% while the NIFTY 500 moved +257%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 14 August 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: operating margin down 18 points on a year earlier and indian funds and insurers (DIIs) raised their stake for 3 quarters in a row.

1. Operating margin down 18 points on a year earlier

   25% in the June 2026 quarter, from 43%.

   Why: The quarter had almost no Revlimid sales, a high margin product that had lifted the year earlier quarter, while growth in the base business only partly filled the gap.

   Next results: check whether Adcock's profit holds beyond the flu season and whether the base business keeps growing, since management said not to treat the flu season lift as recurring.

   From the earnings call on 14 Aug 2026.

2. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row

   From 5.4% to 6.2% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Natco Pharma reported revenue of ₹735 crore, down 44.7% from ₹1,329 crore a year earlier, and a profit of ₹206 crore, down 57.1% from ₹480 crore.

Natco Pharma results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Natco Pharma's management discussed these results on a call held on 14 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Natco Pharma closed at ₹788.75 on 4 November 2026, down 1.7% from ₹802.50 a year earlier (7 November 2025) and down 8.3% over five years. Its highest weekly close since February 2016 was ₹1,582.50 on 13 September 2024.

Natco Pharma share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 26 February 2016 to 4 November 2026.

4 Nov 2026: Natco Pharma closed at ₹788.75, up 0.8% on the week and down 4.0% on the month. 20 Aug 2026: ex-date for an interim dividend of ₹1.50 a share.

Earlier

• 14 Aug 2026: Natco Pharma held its results call for April to June 2026. Management guided: FY27 profit around ₹750 crore; CEO reaffirmed it under Q&A, conflicting with an earlier answer citing about ₹1,200 crore profit and gross sales of 33-34 billion.
• Results for April to June 2026: Revenue down 44.7% and profit down 57.1% on a year earlier.
• 18 Feb 2026: ex-date for an interim dividend of ₹1.50 a share.
• 20 Nov 2025: ex-date for an interim dividend of ₹1.50 a share.

The last was an interim dividend of ₹1.50 a share, ex-date 20 August 2026.

Natco Pharma dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

We do not print a yield for Natco Pharma: one of its dividend records from the last 12 months could not be read cleanly or matched to today’s share count, and we do not guess.

Yes. Natco Pharma Ltd paid out 6% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 14 August 2026, Natco Pharma's management guided: FY27 profit around ₹750 crore; CEO reaffirmed it under Q&A, conflicting with an earlier answer citing about ₹1,200 crore profit and gross sales of 33-34 billion.

“Wait, wait, wait, wait one second. Do not annualize it. It is a seasonal increase because it was a flu season. Our guidance still remains around Rs 750 crores. I am not changing the guidance.”Rajeev Nannapaneni, on the call for April to June 2026

What management guided

• Domestic revenue expected to increase about 25% in FY27 because of Semaglutide.
• Crop Health Sciences expected to break even in FY27, with Q2 significantly better than Q1.
• Organic capital spending at ₹250-300 crores annually.
• Carfilzomib plant upgrade expected complete by year-end and launch remains on track; two unnamed US launches expected next financial year; internal goals are 8-10 ANDAs and 2-3 FTFs annually, with 1-2 FTFs planned this year.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 14 August 2026.

When Natco Pharma reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Crop Health Sciences Q2 improvement and progress toward annual break-even - check whether delayed cropping activity reverses the Q1 loss.

Natco Pharma is on 3 of our India lists: 52 week high & low, Small & mid cap stocks and Pharma stocks.

Natco Pharma Ltd earned ₹206 Cr of net profit in the Jun 2026 quarter, −57.1% on the same quarter a year earlier. Full-year FY26 profit was ₹1,418 Cr. Over 10 years profit has grown 24.7% a year on average. That is 28.0% of the quarter's revenue. The same quarter a year earlier earned ₹480 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Why profit moved: revenue changed −44.7% on a year earlier and the margin moved −18.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −25.0% and revenue −12.2%. Profit is growing slower than sales: rising costs are taking part of the growth.

Natco Pharma Ltd reported ₹735 Cr of revenue in the Jun 2026 quarter, −44.7% on the same quarter a year earlier. Over 10 years it has grown 14.6% a year on average. The last full year, FY26, came in at ₹4,078 Cr. The last four reported quarters add to ₹3,484 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹4,078 Cr, −7.9% on the year before.

Recent pace: the last four quarters grew −12.2% on average, against 14.6% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −20.7%, against −9.1% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −32.5%, against −16.4% a year (rolling over).

Natco Pharma Ltd's operating margin was 25.0% in the Jun 2026 quarter, 18.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 14.0% and 50.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −17.6 percentage points on the year while gross margin changed −2.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 100% of Natco Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,768 Cr of operating cash against ₹1,418 Cr of profit. After ₹381 Cr of spending on assets, ₹1,387 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 100% of profit came in as cash: the cash cycle got 196 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 2.0× depreciation over three years. The next section checks what that spending is building.

Natco Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 343 days in FY26, down from 539 days in FY21. It spent ₹1,235 Cr on assets over the last 3 years. Customers take 79 days to pay, and stock sits for 480 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹4,078 Cr, each day of that cycle ties up about ₹11.2 Cr, so roughly ₹3,832 Cr is tied up in the business at any time.

FY26: customers took 79 days to pay and stock sat for 480 days, about 15.8 months of sales sitting as stock, for a full cycle of 343 days, shorter than FY21's 539.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 480 days. Customers pay about 79 days after that. Suppliers are paid at 216 days. Together that makes the 343-day cycle.

Spending on assets: ₹1,235 Cr over the last 3 years, against ₹629 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹294 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Natco Pharma Ltd's P/E is 13.5×, near the low end of its own history: it has been lower only 17% of the time. Its usual P/E (the middle reading) is 24.1×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.